Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
BURLINGTON, Mass., March 03, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
- Raymond James 38th Annual Institutional Investors Conference
Dr. Clayman will present on Tuesday, March 7, 2017 at 7:30 a.m. EST
- Cowen & Company 37th Annual Health Care Conference
Dr. Clayman will present on Wednesday, March 8, 2017 at 8:00 a.m. EST
To access the live webcast and subsequent archived recordings for the presentations, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, ZilrettaTM (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contacts: Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected] Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
